ELOX
Eloxx Pharmaceuticals, Inc.
13.90$
+1.1%
vs. previous close
Closing price · As of: Oct 12, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11,360.2% | -1,692.7% | -3,795.6% | -677.2% | -526.7% | -1,441.0% | -3,387.9% | – | -2,193.0% | – | -4,868.1% | -9,792.9% | -4,901.6% | – | – | – | – | – | – | – | -74.1% | – | |
| 182.5% | 35.0% | 60.2% | 55.4% | 21.2% | 40.6% | 90.4% | – | 129.0% | – | 349.7% | 236.1% | 124.5% | – | – | – | – | – | – | – | 2.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 8.5% | – | |
| 973.4% | -15.4% | 101.1% | 28.0% | 21.7% | -123.5% | -289.7% | – | -96.3% | – | 1,029.4% | -1,464.9% | -282.3% | – | – | – | – | – | – | – | -37.0% | – | |
| 25.4% | 4.8% | 0.0% | 0.7% | 0.6% | 1.5% | 0.8% | – | 2.2% | – | 3.2% | 163.5% | 0.0% | – | – | – | – | – | – | – | 0.0% | – | |
| -13,204.6% | -622.1% | 3,821.0% | 34.0% | -222.0% | -485.0% | 172.1% | – | -225.2% | – | 646.9% | -346.1% | – | – | – | – | – | – | – | – | 0.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 48.1% | – | |
| 23,762.7% | 2,399.3% | 14.5% | 673.0% | 1,902.5% | – | 8,677.1% | – | 1,614.0% | – | 8,730.2% | 6,436.8% | 1,536.5% | – | – | – | – | – | – | – | 54.1% | – | |
| 1,117.5% | 84.5% | 39.9% | 29.9% | 1,153.8% | -1,926.0% | 5,461.2% | – | -1,805.0% | – | 4,509.0% | -3,702.3% | -3,365.1% | – | – | – | – | – | – | – | -19.5% | – | |
| -11,385.6% | -1,697.5% | -3,795.6% | -677.9% | -527.3% | -1,442.5% | -3,388.7% | – | -2,195.3% | – | -4,871.3% | -9,956.5% | -4,901.6% | – | – | – | – | – | – | – | -74.1% | – |
Data as of: October 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.